OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0000887247

DMK PHARMACEUTICALS Corp

DMK PHARMACEUTICALS Corp (CIK 0000887247, EIN 82-0429727) reported revenue of $4.76 million ($4,756,078) for FY2022 (2022-01-01 to 2022-12-31) and net income of -$26.48 million (-$26,478,273) for FY2022 (2022-01-01 to 2022-12-31), as filed in its 10-K filed 2023-03-16 (accession 0001387131-23-003523).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0000887247
EIN82-0429727
SIC industry code2834 Pharmaceutical Preparations
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_175cyk9ns83ar5rmyb9tgw0858
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$4,756,078FY20222022-01-01 to 2022-12-3110-K2023-03-160001387131-23-003523Revenues
Net income-$26,478,273FY20222022-01-01 to 2022-12-3110-K2023-03-160001387131-23-003523NetIncomeLoss
Total assets$10,930,840FY2022as of 2022-12-3110-K2023-03-160001387131-23-003523Assets
Total liabilities$11,581,605FY2022as of 2022-12-3110-K2023-03-160001387131-23-003523Liabilities
Stockholders' equity-$808,068FY2022as of 2022-12-3110-K2023-03-160001387131-23-003523StockholdersEquity
Operating cash flow-$25,900,506FY20222022-01-01 to 2022-12-3110-K2023-03-160001387131-23-003523NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$0.18 per shareFY20222022-01-01 to 2022-12-3110-K2023-03-160001387131-23-003523EarningsPerShareDiluted
Shares outstanding149,983,265 sharesFY2022as of 2023-03-1310-K2023-03-160001387131-23-003523EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2013-2022, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20222022-01-01 to 2022-12-31$4,756,07810-K2023-03-160001387131-23-003523
RevenueFY20212021-01-01 to 2021-12-31$2,208,68010-K2023-03-160001387131-23-003523
RevenueFY20202020-01-01 to 2020-12-31$2,776,58710-K2022-03-310001387131-22-004483
RevenueFY20192019-01-01 to 2019-12-31$22,113,86910-K2021-04-150001387131-21-004529
RevenueFY20182018-01-01 to 2018-12-31$15,086,64310-K2020-03-300001387131-20-003438
RevenueFY20172017-01-01 to 2017-12-31$13,073,25910-K2019-03-150001387131-19-001966
RevenueFY20162016-01-01 to 2016-12-31$6,473,97810-K2017-03-300001387131-17-001745
Net incomeFY20222022-01-01 to 2022-12-31-$26,478,27310-K2023-03-160001387131-23-003523
Net incomeFY20212021-01-01 to 2021-12-31-$45,828,19810-K2023-03-160001387131-23-003523
Net incomeFY20202020-01-01 to 2020-12-31-$49,391,08910-K2022-03-310001387131-22-004483
Net incomeFY20192019-01-01 to 2019-12-31-$27,512,76910-K2021-04-150001387131-21-004529
Net incomeFY20182018-01-01 to 2018-12-31-$39,006,78210-K2020-03-300001387131-20-003438
Net incomeFY20172017-01-01 to 2017-12-31-$25,538,98010-K2019-03-150001387131-19-001966
Net incomeFY20162016-01-01 to 2016-12-31-$19,437,25210-K2018-03-160001387131-18-001080
Net incomeFY20152015-01-01 to 2015-12-31-$13,571,99710-K2017-03-300001387131-17-001745
Net incomeFY20142013-04-01 to 2014-03-31-$8,155,88010-K2014-06-230001387131-14-002262
  • Revenue for FY2020 was restated: first reported as $16,527,397 (accession 0001387131-21-004529, filed 2021-04-15).
  • Net income for FY2019 was restated: first reported as -$29,306,769 (accession 0001387131-20-003438, filed 2020-03-30).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2023-11-142023-09-300001999371-23-000197dmk-10q_093023.htm
10-Q2023-08-212023-06-300001387131-23-009990admp-10q_063023.htm
10-Q2023-05-152023-03-310001387131-23-006540admp-10q_033123.htm
10-K/A2023-05-012022-12-310001387131-23-005808admp-10ka_123122.htm
10-K2023-03-162022-12-310001387131-23-003523admp-10k_123122.htm
10-Q2022-11-142022-09-300001387131-22-011400admp-10q_093022.htm
10-K/A2022-09-202021-12-310001387131-22-009901admp-10ka_123121.htm
10-Q2022-08-102022-06-300001387131-22-008584admp-10q_063022.htm
10-Q2022-05-162022-03-310001387131-22-006207admp-10q_033122.htm
10-K/A2022-05-022021-12-310001387131-22-005630admp-10ka_123121.htm
10-K2022-03-312021-12-310001387131-22-004483admp-10k_123121.htm
10-Q2021-11-222021-06-300001387131-21-011421admp-10q_063021.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0000887247published by the sourcedata.sec.gov/submissions/CIK0000887247.json2026-10-21
Employer Identification Number (EIN) · US-EIN82-0429727published by the sourcedata.sec.gov/submissions/CIK0000887247.json2026-10-21

Former names

NameFromTo
Adamis Pharmaceuticals Corp2009-04-082023-09-01
CELLEGY PHARMACEUTICALS INC1996-07-092009-04-03

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0000887247.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0000887247.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000887247" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000887247/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000887247/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"887247"}

On SEC EDGAR

About this data